DE69939155D1 - Disulfiram enthaltende arzneimittel - Google Patents

Disulfiram enthaltende arzneimittel

Info

Publication number
DE69939155D1
DE69939155D1 DE69939155T DE69939155T DE69939155D1 DE 69939155 D1 DE69939155 D1 DE 69939155D1 DE 69939155 T DE69939155 T DE 69939155T DE 69939155 T DE69939155 T DE 69939155T DE 69939155 D1 DE69939155 D1 DE 69939155D1
Authority
DE
Germany
Prior art keywords
disciple
products containing
medicinal products
disulfiram
containing disulfiram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939155T
Other languages
German (de)
English (en)
Inventor
Moshe Marikovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69939155D1 publication Critical patent/DE69939155D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DE69939155T 1998-01-11 1999-01-11 Disulfiram enthaltende arzneimittel Expired - Lifetime DE69939155D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate
PCT/IL1999/000017 WO1999034784A2 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
DE69939155D1 true DE69939155D1 (de) 2008-09-04

Family

ID=11071076

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939155T Expired - Lifetime DE69939155D1 (de) 1998-01-11 1999-01-11 Disulfiram enthaltende arzneimittel

Country Status (9)

Country Link
US (1) US6288110B1 (enExample)
EP (1) EP1047416B1 (enExample)
JP (1) JP2002500180A (enExample)
AT (1) ATE401879T1 (enExample)
AU (1) AU1888599A (enExample)
DE (1) DE69939155D1 (enExample)
DK (1) DK1047416T3 (enExample)
IL (1) IL122892A0 (enExample)
WO (1) WO1999034784A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6589987B2 (en) * 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
ATE552837T1 (de) * 2005-12-02 2012-04-15 Univ Johns Hopkins Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2012028311A1 (en) * 2010-08-31 2012-03-08 Avidal Vascular Gmbh Compositions comprising a taxane for coating medical devices
JP6206939B2 (ja) * 2011-10-11 2017-10-04 国立大学法人 千葉大学 肝がん幹細胞阻害剤
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20160346231A1 (en) * 2014-02-06 2016-12-01 Texas Tech University System Disulfiram Compositions and Treatments for Brain Tumors
GB201407806D0 (en) 2014-05-02 2014-06-18 Ucl Business Plc Treatment of fibrosis
GB201519643D0 (en) * 2015-11-06 2015-12-23 Univ Wolverhampton Disulfiram formulation
EP3449919B1 (en) 2016-04-13 2024-05-01 University of Wolverhampton Method for treating pleuroperitoneal membrane cancers by locally injecting disulfiram preparation
EP3311843A1 (en) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
EP3597221B1 (en) 2017-03-17 2023-08-30 Osaka University Agents for the treatment of retinal degeneration and conditions associated with light reception
BR112020025018A2 (pt) * 2018-06-27 2021-03-23 Children's Medical Center Corporation compostos para inibição de inflamação
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3693740A1 (en) 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved dithiocarmabate based compounds, therapies and diagnostics
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
CA3173515A1 (en) * 2020-04-16 2021-10-21 Steven C. Quay Compositions and methods to reduce the infectivity of a virus
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
CN114376997B (zh) * 2021-10-10 2023-04-28 深圳市人民医院 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284879A3 (en) * 1987-03-17 1990-10-17 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
EP1047416B1 (en) 2008-07-23
WO1999034784A3 (en) 2000-09-08
DK1047416T3 (da) 2008-11-17
AU1888599A (en) 1999-07-26
US6288110B1 (en) 2001-09-11
WO1999034784A2 (en) 1999-07-15
JP2002500180A (ja) 2002-01-08
IL122892A0 (en) 1998-08-16
ATE401879T1 (de) 2008-08-15
EP1047416A2 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
DE69939155D1 (de) Disulfiram enthaltende arzneimittel
ATE147618T1 (de) Kosmetisches und/oder dermatologisches mittel enthaltend thermal- oder mineralwasser und einen gegen akne oder älterung aktiven agentsien
IT1212739B (it) Composti eterociclici in cui l'eterosostituente e'ossigeno,zolfo,so,s o2 oppure nr2,utili nel trattamento delle neoplasie e dermatosi
FR2771004B1 (fr) Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse
FI935306L (fi) Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana
EP0706373A4 (en) TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE
IT8803711A0 (it) Apparecchiatura per prevenire la formazione e curare le piaghe da decubito in pazienti lungodegenti
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
DE69017654D1 (de) Äusserlich anzuwendende analgetische lotion und verfahren zur herstellung.
IT8620298A0 (it) Sali di diacetilreina e loro impiego terapeutico nel trattamento dell'artrosi.
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
DE68913739D1 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
FI941345A7 (fi) Retinoidit ja niiden käyttö ihosairauksien ja leukemian hoitoon
IT8703665A0 (it) Apparecchiature od accessori medici procedimento per la igienizzazione ed in particolare di riuniti odoncontinua dei condotti di scarico di toiatrici,e prodotto igienizzante per l'attuazione di tale procedimento
DE59904042D1 (de) Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor
FI950725A7 (fi) Trisyklisen yhdisteen käyttö muistin ja tajunnan häiriöiden hoitoon tarkoitettujen lääkevalmisteiden valmistukseen
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
WO1999034763A3 (en) Pharmaceutical compositions comprising thiram for inhibiting angiogenesis
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
KR930702016A (ko) 골다공증 치료제
IT1244562B (it) Agente per la prevenzione ed il trattamento dell'opacita' del cristallino.
FI942941L (fi) Humaaniproteiini C:n käyttö trombosyyttien saostumisen estämiseen ja hoitoon
ATE147970T1 (de) Duschlotionen zur behandlung und pflege trockener haut

Legal Events

Date Code Title Description
8364 No opposition during term of opposition